Show simple item record

dc.contributor.authorRazi, E. D.en
dc.contributor.authorKalogeras, K. T.en
dc.contributor.authorKotoula, V.en
dc.contributor.authorEleftheraki, A. G.en
dc.contributor.authorNikitas, N.en
dc.contributor.authorKronenwett, R.en
dc.contributor.authorTimotheadou, E.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorPectasides, Dimitriosen
dc.contributor.authorGogas, H.en
dc.contributor.authorWirtz, R. M.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorBafaloukos, Dimitriosen
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorTelevantou, D.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorFountzilas, Georgeen
dc.creatorRazi, E. D.en
dc.creatorKalogeras, K. T.en
dc.creatorKotoula, V.en
dc.creatorEleftheraki, A. G.en
dc.creatorNikitas, N.en
dc.creatorKronenwett, R.en
dc.creatorTimotheadou, E.en
dc.creatorChristodoulou, C.en
dc.creatorPectasides, Dimitriosen
dc.creatorGogas, H.en
dc.creatorWirtz, R. M.en
dc.creatorMakatsoris, T.en
dc.creatorBafaloukos, Dimitriosen
dc.creatorAravantinos, Gerasimosen
dc.creatorTelevantou, D.en
dc.creatorPavlidis, Nicholasen
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:53:02Z
dc.date.available2018-06-22T09:53:02Z
dc.date.issued2012
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41623
dc.description.abstractBackground: Chemokines are important in cell migration and are thought to play a key role in metastasis. We explored the prognostic significance of C-X-C ligand-motif (CXCL) 12, CXCL13, and receptor (CXCR) 5 on disease-free survival (DFS) and overall survival (OS) in early breast cancer. Methods: A total of 595 patients at high risk for early breast cancer were treated in a 2-arm trial (HE10/97) with dose-dense sequential epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with or without paclitaxel. RNA was extracted from 321 formalin-fixed paraffin-embedded primary tumor tissue samples and quantitative reverse-transcriptase polymerase chain reaction was used to assess messenger RNA (mRNA) expression of CXCL12, CXCL13, and CXCR5; estrogen receptor; progesterone receptor (PgR); microtubule-associated protein tau and human epidermal growth factor receptor 2 (HER2). Results: CXCL13 and CXCR5 were found to be negatively associated with estrogen receptor and microtubule-associated protein tau mRNA expression and with dense lymphocytic infiltration, and were positively associated with nuclear grade. Only CXCL13 was positively associated with HER2. Multivariate analysis revealed an association between high CXCL13 mRNA expression and improved DFS (hazard ratio [HR] 0.48 [95% CI, 0.25-0.90]; Wald, P =.023) but not OS; whereas high CXCL12 expression was significantly associated with increased OS (HR 0.53 [95% CI, 0.33-0.85]; Wald, P =.009). In the HER2 mRNA overexpressing subgroup, high CXCL13 mRNA expression was associated with improved DFS (P <.001), whereas high CXCR5 was associated with increased DFS and OS (P =.004 and P =.049, respectively). Conclusions: The CXCL13-CXCR5 axis is associated with classic determinants of poor prognosis, such as high grade, hormone receptor negativity, and axillary node involvement. Interestingly, this chemokine axis seems to be strongly associated with improved outcome in patients with HER2+ disease. © 2012 Elsevier Inc.en
dc.language.isoengen
dc.sourceClinical Breast Canceren
dc.subjectArticleen
dc.subjectCancer chemotherapyen
dc.subjectCyclophosphamideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast canceren
dc.subjectCancer patienten
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectCancer survivalen
dc.subjectPaclitaxelen
dc.subjectHuman tissueen
dc.subjectCancer stagingen
dc.subjectDisease free survivalen
dc.subjectGranulocyte colony stimulating factoren
dc.subjectOverall survivalen
dc.subjectCancer prognosisen
dc.subjectHazard ratioen
dc.subjectMultivariate analysisen
dc.subjectOutcome assessmenten
dc.subjectEpirubicinen
dc.subjectProtein expressionen
dc.subjectCancer risken
dc.subjectCancer adjuvant therapyen
dc.subjectMultiple cycle treatmenten
dc.subjectQuantitative assayen
dc.subjectMessenger rnaen
dc.subjectReverse transcription polymerase chain reactionen
dc.subjectEpidermal growth factor receptor 2en
dc.subjectCancer tissueen
dc.subjectParaffinen
dc.subjectTau proteinen
dc.subjectEstrogen receptoren
dc.subjectProgesterone receptoren
dc.subjectFormaldehydeen
dc.subjectRna extractionen
dc.subjectChemokine receptor cxcr4en
dc.subjectChemokine receptor cxcr5en
dc.subjectChemokinesen
dc.subjectCxcl12en
dc.subjectCxcl13en
dc.subjectCxcl13 chemokineen
dc.subjectCxcr5en
dc.subjectHuman epidermal growth factor receptor 2en
dc.subjectProtein motifen
dc.subjectTissue fixationen
dc.subjectTumor associated leukocyteen
dc.titleImproved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expressionen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.clbc.2012.03.006
dc.description.volume12
dc.description.issue3
dc.description.startingpage183
dc.description.endingpage193
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidAravantinos, Gerasimos [0000-0002-2106-1713]
dc.contributor.orcidKotoula, V. [0000-0002-8657-9732]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-2106-1713
dc.gnosis.orcid0000-0002-8657-9732


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record